Comparative Efficacy of Biologic Vs. Non-Biologic Therapies in Reactive Arthritis: a 52-Week Cohort Study
Keywords:
Reactive arthritis (ReA), biologic therapy, non-biologic therapy, Tumor Necrosis Factor-alpha (TNF-α) inhibitors.Abstract
This study aims to compare the efficacy and safety of biologic versus non-biologic therapies in managing Reactive Arthritis (ReA) over 52 weeks. Methods: A cohort of 60 patients diagnosed with ReA was divided into two treatment groups, with 30 patients each receiving either biologic therapies (including TNF-α inhibitors) or non-biologic therapies (standard disease-modifying antirheumatic drugs). Patients were followed prospectively over 52 weeks, and clinical outcomes were assessed using standardized measures, including the Disease Activity Score (DAS28), remission rates, and adverse event profiles. Results: Patients in the biologic therapy group demonstrated significantly greater improvements in DAS28 scores compared to the non-biologic group (mean reduction: 2.8 vs. 1.9; p < 0.05). Remission rates were achieved in 70% of patients in the biologic group versus 50% in the non-biologic group. Adverse events were more frequent in the non-biologic group (40% vs. 25%), with gastrointestinal discomfort being the most common complaint. Both therapies were well-tolerated overall. Conclusion: Biologic therapies offer superior efficacy in reducing disease activity and achieving remission in Reactive Arthritis compared to non-biologic therapies, with a favorable safety profile. These findings support the consideration of biologic agents as a first-line treatment option for patients with moderate to severe ReA. Further studies are warranted to explore long-term outcomes and cost-effectiveness.
References
Sieper, J., Brandt, J., Braun, J., Burgos-Vargas, R., Dougados, M., Van Der Heijde, D., & others. (2002). Reactive arthritis. The Lancet, 359(9301), 763-770.
Braun, J., & Sieper, J. (2007). Spondyloarthritis. The New England Journal of Medicine, 356(10), 1012-1019.
van der Heijde, D., van Tubergen, A., van der Horst-Bruinsma, I. E., Deodhar, A., Mielants, H., Gensler, L. S., & others. (2017). Management of spondyloarthritis. Annals of the Rheumatic Diseases, 76(4), 962-973.
Coates, L. C., Deodhar, A., & Ritchlin, C. T. (2016). Current concepts in the management of psoriatic arthritis. Nature Reviews Rheumatology, 12(5), 249-261.
Singh, J. A., Saag, K. G., Bridges, S. L., & Akl, E. A. (2018). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis & Rheumatology, 67(1), 34-58.
Gladman, D. D., Husted, J., Cook, R., Farewell, V., Ritchlin, C. T., & Shbeeb, M. (2005). Effect of early disease-modifying therapy in psoriatic arthritis. Arthritis & Rheumatology, 52(8), 2505-2512.
Dougados, M., Baeten, D., Sieper, J., Dougados, C., Blanco, R., Braun, J., & others. (2014). The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2014 treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases, 73(7), 478-486.
Poddubnyy, D., Sieper, J., Landewe, R., Mease, P., Gensler, L., Braun, J., & others. (2018). The significance of minimal disease activity in psoriatic arthritis: Results from a multinational study. Arthritis Research & Therapy, 20(1), 277.
Wendling, D., Blanchard, S., Gossec, L., Dubost, J. J., & Grange, L. (2019). Outcome measures for psoriatic arthritis in daily practice: Practical considerations. Joint Bone Spine, 86(5), 555-561.
Gensler, L., Mease, P. J., & Gladman, D. D. (2020). Long-term safety of biologic therapies in psoriatic arthritis: An observational study. Rheumatology, 59(1), 87-95.
